Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically determined differences in P-glycoprotein function: implications for disease risk.

Martin F Fromm1

  • 1Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstr. 112, 70376 Stuttgart, Germany. martin.fromm@ikp-stuttgart.de

Toxicology
|December 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same author

Deorphanisation and functional characterisation of OATP5A1 as transport protein for amino acids and vitamins.

Cellular & molecular biology letters·2026
Same author

Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations.

Clinical pharmacokinetics·2026
Same author

Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data.

Clinical pharmacology and therapeutics·2025
Same author

A quantitative, broad-panel LC-MS/MS method for the analysis of intact steroid conjugates: A novel approach to steroid profiling for biomarker research in corticoid-dependent diseases.

Journal of pharmaceutical and biomedical analysis·2025
Same author

Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study.

Scientific reports·2025
Same journal

Evaluation of 2,2'-Dimorpholinodiethyl Ether (DMDEE) in Pathology, Perinatal, and Genotoxicity Studies.

Toxicology·2026
Same journal

Retraction notice to "Involvement of both intrinsic and extrinsic pathways in hepatoprotection of arjunolic acid against cadmium induced acute damage in vitro" [Toxicology 283 (2011) 129-139].

Toxicology·2026
Same journal

Crystalline silica particles exposure modulated miRNA expression profiles in human macrophage-like THP-1 cells.

Toxicology·2026
Same journal

Sex-specific cellular and molecular mechanisms of PFAS-induced reproductive toxicity.

Toxicology·2026
Same journal

Neurotoxicity and mechanisms of deltamethrin and its metabolite 3-PBA in HT22 cells.

Toxicology·2026
Same journal

Polystyrene nanoplastics impair epithelial barrier establishment and modulate extracellular vesicle release in human bronchial cells cultured at the air-liquid interface.

Toxicology·2026
See all related articles

The MDR1 gene

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Cellular Transport Mechanisms

Background:

  • P-glycoprotein, encoded by the MDR1 gene, is crucial for drug resistance and detoxification in healthy tissues like the intestine, liver, and kidney.
  • It effluxes diverse compounds, influencing the bioavailability of oral medications such as digoxin.
  • Recent discoveries include MDR1 gene mutations affecting P-glycoprotein function.

Purpose of the Study:

  • To investigate the functional impact of the MDR1 C3435T mutation on P-glycoprotein levels and activity.
  • To explore the implications of reduced P-glycoprotein function in specific diseases: inflammatory bowel disease, HIV, and renal cell carcinoma.

Main Methods:

  • Genotyping for the MDR1 C3435T polymorphism.
  • Assessing P-glycoprotein expression and function in intestinal and peripheral blood cells.

Related Experiment Videos

  • Correlating mutation status with disease risk and therapeutic outcomes in selected patient cohorts.

    • Main Results:

    • Homozygosity for C3435T (24% of Caucasians) is linked to lower intestinal P-glycoprotein levels and reduced transporter function.
    • Individuals with this genotype exhibit higher plasma digoxin concentrations after oral administration.
    • Preliminary findings suggest associations between reduced P-glycoprotein expression and increased risk for inflammatory bowel disease, altered HIV disease progression, and renal cell carcinoma.

    Conclusions:

    • The MDR1 C3435T mutation significantly impacts P-glycoprotein-mediated transport, affecting drug bioavailability and cellular detoxification.
    • This genetic variation has potential clinical relevance in predicting disease susceptibility and treatment response across various conditions.
    • Further research is warranted to fully elucidate the clinical implications of MDR1 polymorphisms in pharmacogenomics and disease management.